Central Nervous System Pharmacology Practice Questions

Q: Which of the following is a benzodiazepine receptor antagonist?

Flumazenil. ### Explanation **Correct Option: D. Flumazenil** Flumazenil is a specific **competitive antagonist** at the benzodiazepine (BZD) binding site on the $\text{GABA}_A$ receptor complex. It blocks the effects of benzodiazepines and "Z-drugs" (Zolpidem, Zopiclone) but does not antagonize the effects of barbiturates, ethanol, or general anesthetics, as they bind to different sites on the receptor. **Analysis of Incorrect Options:** * **A. Nalorphine:** A mixed opioid agonist-antagonist. While it can reverse opioid effects, it is rarely used clinically today due to its psychotomimetic side effects. * **B. Carbamazepine:** An anticonvulsant and mood stabilizer that acts primarily by blocking **voltage-gated sodium channels**. It is a first-line treatment for Trigeminal Neuralgia but has no activity at the BZD receptor. * **C. Naloxone:** A competitive **opioid receptor antagonist**. It is the drug of choice for reversing respiratory depression in acute opioid overdose, not BZD overdose. **High-Yield Clinical Pearls for NEET-PG:** * **Indications:** Flumazenil is used for the reversal of BZD-induced conscious sedation and the management of BZD overdose. * **The "Seizure" Risk:** Use flumazenil with extreme caution in patients with long-term BZD dependence or those who have co-ingested TCAs (Tricyclic Antidepressants), as it can precipitate **acute withdrawal seizures**. * **Pharmacokinetics:** It has a very short half-life (~1 hour). Since most benzodiazepines (e.g., Diazepam) last longer, "re-sedation" can occur, requiring repeated doses or an infusion. * **Inverse Agonists:** Remember that **Beta-carbolines** are inverse agonists at the BZD site (causing anxiety/convulsions), and their effects are also blocked by Flumazenil.

Q: What is the mechanism of action of local anesthetics?

Stabilization of the neuronal membrane. ### Explanation **Correct Option: A. Stabilization of the neuronal membrane** Local anesthetics (LAs) act by reversibly binding to the intracellular portion of **voltage-gated sodium channels**. By binding to these channels, they prevent the influx of sodium ions ($Na^+$) into the cell. This prevents the depolarization of the nerve membrane, meaning the threshold potential is never reached and an action potential cannot be generated or conducted. Because the resting membrane potential is maintained and the nerve remains in a non-excitable state, this process is termed **"membrane stabilization."** **Incorrect Options:** * **B & C:** While calcium and magnesium play roles in neurotransmission and membrane excitability, LAs do not primarily target these ions to produce anesthesia. Calcium ions, however, can antagonize the action of LAs (high extracellular $Ca^{2+}$ can decrease LA effectiveness). * **D:** Dopamine release is associated with the central nervous system's reward pathways and motor control; it is not involved in the peripheral block of nerve conduction. **High-Yield NEET-PG Pearls:** * **State-Dependent Block:** LAs have a higher affinity for sodium channels in the **activated (open)** and **inactivated** states rather than the resting state. This is why rapidly firing nerves are blocked faster (use-dependent block). * **Sensitivity:** Small, myelinated fibers (A-delta) and unmyelinated fibers (C-fibers) are generally blocked before large, myelinated fibers. * **Sequence of Blockade:** Autonomic > Sensory (Pain > Temperature > Touch > Proprioception) > Motor. * **Chemistry:** Most LAs are weak bases. In acidic environments (like infected tissue), they become ionized and cannot cross the lipid membrane, leading to reduced efficacy.

Q: Benzodiazepines differ from barbiturates in the following aspects except:

They have a steeper dose-response curve. The core difference between Benzodiazepines (BZDs) and Barbiturates lies in their mechanism of action on the GABA-A receptor and their subsequent safety profiles. **Why Option A is the Correct Answer:** Benzodiazepines actually have a **flatter (shallower) dose-response curve** compared to barbiturates. This is because BZDs are **GABA-facilitatory** (they increase the *frequency* of chloride channel opening) and require endogenous GABA to work. Once GABA receptors are saturated, further increases in BZD dose do not result in further CNS depression. In contrast, Barbiturates have a **steeper dose-response curve** because they are **GABA-mimetic** at high doses (they increase the *duration* of channel opening even in the absence of GABA), leading to progressive CNS depression, coma, and death [1]. **Analysis of Incorrect Options:** * **Option B:** BZDs have a **higher therapeutic index** because of the ceiling effect mentioned above, making them much safer in overdose than barbiturates [2]. * **Option C:** BZDs have **lower abuse liability** and milder withdrawal symptoms compared to the severe physical dependence associated with barbiturates. * **Option D:** BZDs **do not induce** hepatic microsomal enzymes (CYP450), whereas barbiturates are potent enzyme inducers, leading to numerous drug-drug interactions (e.g., with warfarin or oral contraceptives). **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism Mnemonic:** **B**enzodiazepines increase **F**requency (**B-F**); **B**arbiturates increase **D**uration (**B-D**). * **Antidote:** Flumazenil is a specific antagonist for BZD overdose; there is no specific antagonist for barbiturates [1]. * **Contraindication:** Barbiturates are strictly contraindicated in **Acute Intermittent Porphyria** as they induce ALA synthase [1].

Q: Which is the central inhibitor of dopamine metabolism?

Deperenyl. **Explanation:** The correct answer is **Deperenyl** (also known as **Selegiline**). **1. Why Deperenyl is correct:** Dopamine metabolism in the brain occurs primarily via two enzymes: Monoamine Oxidase-B (MAO-B) and Catechol-O-Methyltransferase (COMT). Deperenyl is a selective, irreversible inhibitor of **MAO-B**. By inhibiting this enzyme centrally, it prevents the breakdown of dopamine in the striatum, thereby increasing its bioavailability and prolonging its action. This makes it a key "dopamine sparer" in the management of Parkinson’s disease. **2. Why the other options are incorrect:** * **Carbidopa:** It is a **peripheral** inhibitor of Dopa-decarboxylase. It prevents the conversion of Levodopa to dopamine in the systemic circulation but does not cross the blood-brain barrier (BBB). It does not inhibit dopamine metabolism centrally. * **Orphenadrine:** This is a central **anticholinergic** drug used to manage the cholinergic overactivity (tremors/rigidity) seen in Parkinsonism. It has no direct effect on dopamine metabolism. * **Bromocriptine:** This is a **Dopamine Agonist** (specifically at D2 receptors). It mimics the action of dopamine rather than inhibiting its metabolic breakdown. **3. Clinical Pearls for NEET-PG:** * **MAO Inhibitors:** Selegiline and Rasagiline are selective MAO-B inhibitors. Unlike non-selective MAO inhibitors, they do not typically cause the "Cheese Reaction" (hypertensive crisis) at conventional doses. * **COMT Inhibitors:** **Tolcapone** acts both centrally and peripherally, while **Entacapone** acts only peripherally. * **Metabolic End-product:** The major central metabolite of dopamine is **Homovanillic Acid (HVA)**. * **Drug of Choice:** For drug-induced Parkinsonism, central anticholinergics like **Benztropine** or **Trihexyphenidyl** are preferred over levodopa.

Q: Which of the following statements is FALSE regarding Naltrexone?

Parenterally administered. **Explanation:** **Naltrexone** is a long-acting opioid antagonist used in the management of both Alcohol Use Disorder and Opioid Use Disorder. 1. **Why Option A is FALSE (Correct Answer):** Naltrexone is primarily administered **orally** (50 mg daily). While a long-acting injectable (depot) formulation exists (Vivitrol), the standard pharmacological profile taught for NEET-PG emphasizes its high oral bioavailability and effectiveness via the oral route. In contrast, **Naloxone** (a short-acting antagonist) must be given parenterally because it undergoes extensive first-pass metabolism. Therefore, stating Naltrexone is "parenterally administered" as its defining characteristic is incorrect in this comparative context. 2. **Analysis of Other Options:** * **Option B (Relapse Prevention):** Naltrexone reduces the "high" or craving associated with alcohol by blocking mu-opioid receptors. It is specifically indicated to reduce the frequency of heavy drinking days. * **Option C (Long Acting):** Naltrexone has a significantly longer half-life (approx. 4–13 hours for its active metabolite, 6-beta-naltrexol) compared to Naloxone (approx. 1 hour), making it suitable for maintenance therapy. * **Option D (Hepatotoxicity):** Naltrexone carries a dose-related warning for hepatotoxicity. Liver function tests (LFTs) should be monitored during treatment. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism:** Competitive antagonist at $\mu$ (mu) receptors. * **Alcoholism:** First-line for reducing cravings (unlike Disulfiram, which is an aversive agent). * **Opioids:** Patients must be opioid-free for **7–10 days** before starting Naltrexone to avoid precipitating acute withdrawal. * **Contraindication:** Acute hepatitis or liver failure.

Q: What is the drug of choice for Restless Legs Syndrome?

Ropinirole. **Explanation:** **Restless Legs Syndrome (RLS)**, also known as Willis-Ekbom Disease, is a neurological sensory-motor disorder characterized by an irresistible urge to move the legs, usually associated with unpleasant sensations that worsen at rest and during the night. **Why Ropinirole is the Correct Answer:** The pathophysiology of RLS is linked to **dopaminergic dysfunction** in the nigrostriatal pathway and iron deficiency in the CNS. Therefore, **Dopamine Agonists** are the first-line treatment (Drug of Choice). **Ropinirole** and **Pramipexole** (non-ergot dopamine agonists) are FDA-approved and preferred because they directly stimulate D2 and D3 receptors, effectively relieving symptoms and improving sleep quality. **Analysis of Incorrect Options:** * **A. Febuxostat:** A xanthine oxidase inhibitor used for the management of chronic hyperuricemia in Gout. It has no role in dopamine modulation. * **B. Diazepam:** A benzodiazepine used for anxiety and muscle spasms. While it may help with sleep onset, it does not treat the underlying sensory-motor urge of RLS and carries a risk of dependence. * **D. Baclofen:** A GABA-B agonist used as a centrally acting muscle relaxant for spasticity (e.g., Multiple Sclerosis). It is not effective for RLS. **High-Yield Clinical Pearls for NEET-PG:** 1. **First-line agents:** Ropinirole, Pramipexole, and Rotigotine (transdermal patch). 2. **Alternative/Second-line:** Gabapentin enacarbil or Pregabalin (preferred if the patient has comorbid neuropathy or insomnia). 3. **Iron Stores:** Always check **Serum Ferritin** levels. Iron supplementation is indicated if ferritin is <75 µg/L, as iron is a cofactor for tyrosine hydroxylase (the rate-limiting enzyme in dopamine synthesis). 4. **Augmentation:** A unique side effect where long-term dopamine agonist use causes symptoms to start earlier in the day or become more severe.

Q: What is the drug of choice for nocturnal enuresis?

Imipramine. **Explanation:** **Imipramine** is a Tricyclic Antidepressant (TCA) and is considered the drug of choice for the pharmacological management of **nocturnal enuresis** (bedwetting) in children above 6 years of age. Its efficacy is attributed to a triple mechanism of action: 1. **Anticholinergic effect:** It increases the bladder capacity by relaxing the detrusor muscle. 2. **Alpha-adrenergic stimulation:** It increases the tone of the internal urethral sphincter. 3. **Alteration of sleep architecture:** It lightens the depth of sleep, making the child more likely to wake up when the bladder is full. **Analysis of Incorrect Options:** * **Diazepam:** A benzodiazepine used for anxiety and seizures. It deepens sleep (Stage 4), which could potentially worsen enuresis. * **Amoxapine:** A tetracyclic antidepressant with dopamine-blocking properties. It is primarily used for major depression with psychotic features, not enuresis. * **Reboxetine:** A selective norepinephrine reuptake inhibitor (SNRI) used for depression; it lacks the significant anticholinergic profile required to treat enuresis effectively. **Clinical Pearls for NEET-PG:** * **First-line management:** Non-pharmacological therapy (bladder training and **enuresis alarms**) is always preferred before starting drugs. * **Alternative Drug:** **Desmopressin** (ADH analogue) is often preferred in modern practice due to a better safety profile, but in the context of classic pharmacology questions, Imipramine remains the standard answer. * **Caution:** Imipramine has a narrow therapeutic index; overdose can lead to life-threatening cardiac arrhythmias (QRS prolongation).

Q: Which of the following does not belong to the ester group of local anesthetics?

Dibucaine. Local anesthetics (LAs) are chemically classified into two categories based on the linkage between their aromatic and hydrophilic groups: **Esters** and **Amides**. ### 1. Why Dibucaine is the Correct Answer **Dibucaine** belongs to the **Amide group**. A simple high-yield rule for NEET-PG is the **"i" rule**: Amide local anesthetics have two "i"s in their name (e.g., L**i**doca**i**ne, Pr**i**loca**i**ne, Bup**i**vaca**i**ne, D**i**buca**i**ne), whereas Ester local anesthetics have only one "i" (e.g., Procaine, Benzocaine). Dibucaine is a potent, long-acting amide primarily used in spinal anesthesia and topical preparations. ### 2. Analysis of Incorrect Options * **A. Chloroprocaine:** An ester-linked LA. It is known for its rapid onset and short duration of action, often used in obstetrics because it is rapidly metabolized by plasma cholinesterase, minimizing fetal exposure. * **B. Tetracaine:** A potent, long-acting ester LA. It is frequently used for spinal and topical (ophthalmic) anesthesia. * **C. Benzocaine:** An ester LA. Due to its low solubility, it is used exclusively for topical anesthesia. It is a known cause of methemoglobinemia. ### 3. Clinical Pearls for NEET-PG * **Metabolism:** Esters are metabolized by **plasma pseudocholinesterase** (deficiency leads to prolonged action), while Amides are metabolized by **hepatic microsomal enzymes** (CYP450). * **Allergy:** Allergic reactions are more common with **Esters** due to the metabolite **Para-aminobenzoic acid (PABA)**. Amide allergies are extremely rare. * **Dibucaine Number:** This is a clinical test to identify individuals with atypical pseudocholinesterase. Dibucaine inhibits normal enzyme activity by 80%, but atypical enzyme by only 20%. A low Dibucaine number indicates a risk of prolonged apnea after succinylcholine administration.

Q: Which of the following is NOT a dopaminergic agonist used for the management of Parkinsonism?

Selegiline. ### Explanation The correct answer is **Selegiline** because it is a **Selective irreversible MAO-B inhibitor**, not a direct dopaminergic agonist. #### 1. Why Selegiline is the Correct Answer Selegiline works by inhibiting the enzyme **Monoamine Oxidase-B (MAO-B)**, which is responsible for the degradation of dopamine in the striatum. By blocking this enzyme, it increases the availability and prolongs the action of endogenous or exogenous dopamine. It does not directly stimulate dopamine receptors. #### 2. Analysis of Incorrect Options (Dopamine Agonists) These drugs act by directly stimulating dopamine receptors (primarily D2 and D3) in the brain: * **Bromocriptine (Option A):** An older, **Ergot-derived** dopamine agonist. Its use has declined due to side effects like retroperitoneal/pulmonary fibrosis and heart valve erythromelalgia. * **Ropinirole (Option B):** A **Non-ergot** dopamine agonist. It is highly selective for D2/D3 receptors and is frequently used in early Parkinsonism and Restless Leg Syndrome. * **Pramipexole (Option C):** Another **Non-ergot** agonist with antioxidant properties. Like Ropinirole, it is preferred over ergot derivatives due to a better safety profile. #### 3. NEET-PG High-Yield Pearls * **Cheese Reaction:** Selegiline is selective for MAO-B at low doses, so it **does not** typically cause the "cheese reaction" (hypertensive crisis) associated with non-selective MAO inhibitors. However, selectivity is lost at higher doses. * **Metabolism:** Selegiline is metabolized into **amphetamine and methamphetamine**, which can cause insomnia as a side effect. * **Neuroprotection:** Selegiline is hypothesized to have neuroprotective effects by reducing oxidative stress, though clinical evidence remains debated. * **Apomorphine:** Remember that Apomorphine is a potent injectable dopamine agonist used for "rescue" therapy during "off" episodes in advanced Parkinson’s.

Question 1

Which of the following is a benzodiazepine receptor antagonist?

Accepted Answer

Flumazenil

Answer

Nalorphine

Answer

Carbamazepine

Answer

Naloxone

Question 2

What is the mechanism of action of local anesthetics?

Accepted Answer

Stabilization of the neuronal membrane

Answer

Inhibition of calcium ion influx

Answer

Inhibition of magnesium ion transport

Answer

Increasing dopamine release

Question 3

Benzodiazepines differ from barbiturates in the following aspects except:

Accepted Answer

They have a steeper dose-response curve

Answer

They have a higher therapeutic index

Answer

They have lower abuse liability

Answer

They do not induce microsomal drug-metabolizing enzymes

Question 4

Which is the central inhibitor of dopamine metabolism?

Accepted Answer

Deperenyl

Answer

Carbidopa

Answer

Orphenadrine

Answer

Bromocriptine

Question 5

Allergic reactions in patients who receive amide-type local anesthetics for dental procedures are most likely caused by reaction of what substance?

Accepted Answer

Methylparaben

Answer

Contaminants

Answer

Lignocaine hydrochloride

Answer

Epinephrine

Question 6

Which of the following statements is FALSE regarding Naltrexone?

Accepted Answer

Parenterally administered

Answer

Used to prevent relapse of heavy drinking

Answer

Long acting

Answer

Causes hepatotoxicity

Question 7

What is the drug of choice for Restless Legs Syndrome?

Accepted Answer

Ropinirole

Answer

Febuxostat

Answer

Diazepam

Answer

Baclofen

Question 8

What is the drug of choice for nocturnal enuresis?

Accepted Answer

Imipramine

Answer

Diazepam

Answer

Amoxapine

Answer

Reboxetine

Question 9

Which of the following does not belong to the ester group of local anesthetics?

Accepted Answer

Dibucaine

Answer

Chloroprocaine

Answer

Tetracaine

Answer

Benzocaine

Question 10

Which of the following is NOT a dopaminergic agonist used for the management of Parkinsonism?

Accepted Answer

Selegiline

Answer

Bromocriptine

Answer

Ropinirole

Answer

Pramipexole

Central Nervous System Pharmacology — MCQs

Central Nervous System Pharmacology — MCQs

On this page

Practice by Chapter

Want unlimited practice?